Biosimilars – Access & Reimbursement – Payer Insights Landscape (US/EU)
Payers play a significant role in determining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential reimbursement. Although biosimilars such as Pfizer’s Inflectra and Retacrit are available both in Europe and the United States, their success may vary because of regional differences in the drivers of and barriers to biosimilar uptake. As such, it is necessary for biosimilars developers and manufacturers of branded biologics to understand which factors influence payer decisions regarding biosimilars.
Questions answered:
- What are payers’ perspectives on the drivers of and barriers to biosimilars uptake?
- What factors influence which biosimilars are preferred on formularies in the United States?
- How do payers choose among multiple biosimilars of the same brand in the EU?
- What strategies do payers use to manage biosimilars?
- What expectations do payers have for biosimilars discounts?
- How would the availability of biosimilars influence the pricing of emerging agents?
- Will payer strategies for biosimilars differ between therapeutic specialties?
- Has COVID-19 affected the use or coverage of biosimilars?
Key markets covered:
- France
- Germany
- Italy
- Spain
- United Kingdom
- United States
Key companies mentioned:
- Amgen
- Biocon
- Biogen
- Boehringer Ingelheim
- Celltrion
- Eli Lilly
- Janssen
- Johnson & Johnson
- Merck & Co.
- Mundipharma
- Viatris (Mylan)
- Novartis
- Pfizer
- Roche
- Samsung Bioepis
- Sandoz
- Sanofi
- Teva
Key drugs mentioned:
- Admelog / Insulin Lispro Sanofi
- Aranesp
- Avastin
- Avsola
- Basaglar / Abasaglar
- Benepali
- Binocrit
- Enbrel
- Flixabi
- Fulphila
- Herceptin
- Herzuma
- Hulio
- Humalog
- Humira
- Inflectra
- Kanjinti
- Lantus
- Levemir
- Mvasi
- Neulasta
- Neupogen
- Nivestim / Nivestym
- NovoLog / NovoRapid
- Nyvepria
- Ogivri
- Ontruzant
- Procrit / Epogen
- Remicade
- Remsima
- Retacrit
- Riabni
- Rituxan / MabThera
- Ruxience
- Semglee
- Trazimera
- Truxima
- Udenyca
- Zarzio / Zarxio
- Ziextenzo
- Zirabev
Table of contents
- Biosimilars - Access & Reimbursement - Payer Insights Landscape (US/EU)
- A&R Biosimilars U.S. Payer Insights 2023
- A&R Biosimilars EU5 Payer Insights 2023
Yashu Malhotra, M.Pharm., is an analyst on the Biosimilars and Oncology teams at Clarivate. Previously, she was a senior analyst in the life sciences department at Course5 Intelligence. She also worked in competitive intelligence at WNS Global Services. Ms. Malhotra earned her master’s degree in pharmacy (quality assurance) from India’s Delhi Institute of Pharmaceutical Sciences and Research.
